论文部分内容阅读
目的观察重组人P53腺病毒注射液联合放疗治疗宫颈癌的疗效。方法 40例宫颈癌患者随机分为单纯放疗组(A组)和联合治疗组(B组),每组20例。重组人P53腺病毒瘤内局部注射每周1次,连用4-6次,两组放疗方案一致,治疗结束后3月,复查CT或MR观察肿瘤变化。结果联合治疗组(B组)有效率较单纯放疗组(A组)高(χ2=3.23,P<0.05)。联合治疗组发热发生率较单纯放疗组高,但发热不影响治疗过程,未增加放疗毒副反应。结论重组人P53腺病毒注射液联合放疗治疗宫颈癌具有较好疗效。
Objective To observe the efficacy of recombinant human P53 adenovirus injection combined with radiotherapy in the treatment of cervical cancer. Methods Forty patients with cervical cancer were randomly divided into radiotherapy group (A group) and combination therapy group (B group), with 20 cases in each group. Recombinant human P53 adenovirus within the local injection once a week, once every 4-6 times, the two groups of radiation regimens the same, three months after the end of treatment, review CT or MR tumor changes observed. Results The combined treatment group (group B) was more effective than the radiotherapy alone group (χ2 = 3.23, P <0.05). The incidence of fever in the combination therapy group was higher than that in the radiotherapy alone group, but the fever did not affect the course of treatment, and did not increase the side effects of radiotherapy. Conclusion Recombinant human P53 adenovirus injection combined with radiotherapy for cervical cancer has a good effect.